You are here Home Resources and guidance Sponsors Celgene Pty Limited Regulatory activities for this sponsor. Listen Print Share LinkedIn (Twitter) Facebook Email Loading... Type Prescription medicine decision summary (2) Australian public assessment report (AusPar) (1) Date 2022 (1) 2021 (1) 2020 (1) Search Sponsor content3 result(s) found, displaying 1 to 3 AusPAR: Zeposia 20 September 2022 Australian public assessment report (AusPar) AusPAR for Zeposia (ozanimod) for the treatment of adult patients with moderately to severely active ulcerative colitis. Reblozyl 7 September 2021 Prescription medicine decision summary Australian prescription medicine decision summary Zeposia 27 July 2020 Prescription medicine decision summary Australian prescription medicine decision summary
AusPAR: Zeposia 20 September 2022 Australian public assessment report (AusPar) AusPAR for Zeposia (ozanimod) for the treatment of adult patients with moderately to severely active ulcerative colitis.
Reblozyl 7 September 2021 Prescription medicine decision summary Australian prescription medicine decision summary
Zeposia 27 July 2020 Prescription medicine decision summary Australian prescription medicine decision summary